200 related articles for article (PubMed ID: 30518632)
21. Targeting LSD1 for acute myeloid leukemia (AML) treatment.
Zhang S; Liu M; Yao Y; Yu B; Liu H
Pharmacol Res; 2021 Feb; 164():105335. PubMed ID: 33285227
[TBL] [Abstract][Full Text] [Related]
22. Histone Demethylase LSD1 Inhibitors Prevent Cell Growth by Regulating Gene Expression in Esophageal Squamous Cell Carcinoma Cells.
Hoshino I; Akutsu Y; Murakami K; Akanuma N; Isozaki Y; Maruyama T; Toyozumi T; Matsumoto Y; Suito H; Takahashi M; Sekino N; Komatsu A; Suzuki T; Matsubara H
Ann Surg Oncol; 2016 Jan; 23(1):312-20. PubMed ID: 25791791
[TBL] [Abstract][Full Text] [Related]
23. Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all-
Smitheman KN; Severson TM; Rajapurkar SR; McCabe MT; Karpinich N; Foley J; Pappalardi MB; Hughes A; Halsey W; Thomas E; Traini C; Federowicz KE; Laraio J; Mobegi F; Ferron-Brady G; Prinjha RK; Carpenter CL; Kruger RG; Wessels L; Mohammad HP
Haematologica; 2019 Jun; 104(6):1156-1167. PubMed ID: 30514804
[TBL] [Abstract][Full Text] [Related]
24. Melatonin exerts anti-oral cancer effect via suppressing LSD1 in patient-derived tumor xenograft models.
Yang CY; Lin CK; Tsao CH; Hsieh CC; Lin GJ; Ma KH; Shieh YS; Sytwu HK; Chen YW
Oncotarget; 2017 May; 8(20):33756-33769. PubMed ID: 28422711
[TBL] [Abstract][Full Text] [Related]
25. Inhibitors of LSD1 as a potential therapy for acute myeloid leukemia.
Przespolewski A; Wang ES
Expert Opin Investig Drugs; 2016 Jul; 25(7):771-80. PubMed ID: 27077938
[TBL] [Abstract][Full Text] [Related]
26. Interference of lysine-specific demethylase 1 inhibits cellular invasion and proliferation in vivo in gastric cancer MKN-28 cells.
Li Y; Tian X; Sui CG; Jiang YH; Liu YP; Meng FD
Biomed Pharmacother; 2016 Aug; 82():498-508. PubMed ID: 27470390
[TBL] [Abstract][Full Text] [Related]
27. Reversible inhibition of lysine specific demethylase 1 is a novel anti-tumor strategy for poorly differentiated endometrial carcinoma.
Theisen ER; Gajiwala S; Bearss J; Sorna V; Sharma S; Janat-Amsbury M
BMC Cancer; 2014 Oct; 14():752. PubMed ID: 25300887
[TBL] [Abstract][Full Text] [Related]
28. Silencing of LSD1 gene modulates histone methylation and acetylation and induces the apoptosis of JeKo-1 and MOLT-4 cells.
Zou ZK; Huang YQ; Zou Y; Zheng XK; Ma XD
Int J Mol Med; 2017 Aug; 40(2):319-328. PubMed ID: 28627608
[TBL] [Abstract][Full Text] [Related]
29. Characterization of activating mutations of NOTCH3 in T-cell acute lymphoblastic leukemia and anti-leukemic activity of NOTCH3 inhibitory antibodies.
Bernasconi-Elias P; Hu T; Jenkins D; Firestone B; Gans S; Kurth E; Capodieci P; Deplazes-Lauber J; Petropoulos K; Thiel P; Ponsel D; Hee Choi S; LeMotte P; London A; Goetcshkes M; Nolin E; Jones MD; Slocum K; Kluk MJ; Weinstock DM; Christodoulou A; Weinberg O; Jaehrling J; Ettenberg SA; Buckler A; Blacklow SC; Aster JC; Fryer CJ
Oncogene; 2016 Nov; 35(47):6077-6086. PubMed ID: 27157619
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis, and structure-activity relationship of novel LSD1 inhibitors based on pyrimidine-thiourea hybrids as potent, orally active antitumor agents.
Ma LY; Zheng YC; Wang SQ; Wang B; Wang ZR; Pang LP; Zhang M; Wang JW; Ding L; Li J; Wang C; Hu B; Liu Y; Zhang XD; Wang JJ; Wang ZJ; Zhao W; Liu HM
J Med Chem; 2015 Feb; 58(4):1705-16. PubMed ID: 25610955
[TBL] [Abstract][Full Text] [Related]
31. Novel potent inhibitors of the histone demethylase KDM1A (LSD1), orally active in a murine promyelocitic leukemia model.
Trifirò P; Cappa A; Brambillasca S; Botrugno OA; Cera MR; Zuffo RD; Dessanti P; Meroni G; Thaler F; Villa M; Minucci S; Mercurio C; Varasi M; Vianello P
Future Med Chem; 2017 Jul; 9(11):1161-1174. PubMed ID: 28722470
[TBL] [Abstract][Full Text] [Related]
32. Biochemical, structural, and biological evaluation of tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and LSD2.
Binda C; Valente S; Romanenghi M; Pilotto S; Cirilli R; Karytinos A; Ciossani G; Botrugno OA; Forneris F; Tardugno M; Edmondson DE; Minucci S; Mattevi A; Mai A
J Am Chem Soc; 2010 May; 132(19):6827-33. PubMed ID: 20415477
[TBL] [Abstract][Full Text] [Related]
33. Novel lncRNA-IUR suppresses Bcr-Abl-induced tumorigenesis through regulation of STAT5-CD71 pathway.
Wang X; Yang J; Guo G; Feng R; Chen K; Liao Y; Zhang L; Sun L; Huang S; Chen JL
Mol Cancer; 2019 Apr; 18(1):84. PubMed ID: 30961617
[TBL] [Abstract][Full Text] [Related]
34. The histone demethylase LSD1 is a novel oncogene and therapeutic target in oral cancer.
Wang Y; Zhu Y; Wang Q; Hu H; Li Z; Wang D; Zhang W; Qi B; Ye J; Wu H; Jiang H; Liu L; Yang J; Cheng J
Cancer Lett; 2016 Apr; 374(1):12-21. PubMed ID: 26872725
[TBL] [Abstract][Full Text] [Related]
35. Discovery of higenamine as a potent, selective and cellular active natural LSD1 inhibitor for MLL-rearranged leukemia therapy.
Fang Y; Yang C; Teng D; Su S; Luo X; Liu Z; Liao G
Bioorg Chem; 2021 Apr; 109():104723. PubMed ID: 33618250
[TBL] [Abstract][Full Text] [Related]
36. Discovery of a Novel Inhibitor of Histone Lysine-Specific Demethylase 1A (KDM1A/LSD1) as Orally Active Antitumor Agent.
Vianello P; Botrugno OA; Cappa A; Dal Zuffo R; Dessanti P; Mai A; Marrocco B; Mattevi A; Meroni G; Minucci S; Stazi G; Thaler F; Trifiró P; Valente S; Villa M; Varasi M; Mercurio C
J Med Chem; 2016 Feb; 59(4):1501-17. PubMed ID: 26702542
[TBL] [Abstract][Full Text] [Related]
37. A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC.
Mohammad HP; Smitheman KN; Kamat CD; Soong D; Federowicz KE; Van Aller GS; Schneck JL; Carson JD; Liu Y; Butticello M; Bonnette WG; Gorman SA; Degenhardt Y; Bai Y; McCabe MT; Pappalardi MB; Kasparec J; Tian X; McNulty KC; Rouse M; McDevitt P; Ho T; Crouthamel M; Hart TK; Concha NO; McHugh CF; Miller WH; Dhanak D; Tummino PJ; Carpenter CL; Johnson NW; Hann CL; Kruger RG
Cancer Cell; 2015 Jul; 28(1):57-69. PubMed ID: 26175415
[TBL] [Abstract][Full Text] [Related]
38. LPE-1, an orally active pyrimidine derivative, inhibits growth and mobility of human esophageal cancers by targeting LSD1.
Wang B; Zhao B; Pang LP; Zhao YD; Guo Q; Wang JW; Zheng YC; Zhang XH; Liu Y; Liu GY; Guo WG; Wang C; Li ZH; Mao XJ; Yu B; Ma LY; Liu HM
Pharmacol Res; 2017 Aug; 122():66-77. PubMed ID: 28571892
[TBL] [Abstract][Full Text] [Related]
39. Pure enantiomers of benzoylamino-tranylcypromine: LSD1 inhibition, gene modulation in human leukemia cells and effects on clonogenic potential of murine promyelocytic blasts.
Valente S; Rodriguez V; Mercurio C; Vianello P; Saponara B; Cirilli R; Ciossani G; Labella D; Marrocco B; Monaldi D; Ruoppolo G; Tilset M; Botrugno OA; Dessanti P; Minucci S; Mattevi A; Varasi M; Mai A
Eur J Med Chem; 2015 Apr; 94():163-74. PubMed ID: 25768700
[TBL] [Abstract][Full Text] [Related]
40. NCL1, a highly selective lysine-specific demethylase 1 inhibitor, suppresses prostate cancer without adverse effect.
Etani T; Suzuki T; Naiki T; Naiki-Ito A; Ando R; Iida K; Kawai N; Tozawa K; Miyata N; Kohri K; Takahashi S
Oncotarget; 2015 Feb; 6(5):2865-78. PubMed ID: 25605246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
